Media ReleasesImmutep

View All Immutep News

Immutep announces publication of ELCC 2022 abstract

• New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients
• Combination continues to be safe and well tolerated, and shows encouraging signs of antitumour activity in this difficult to treat patient population with limited treatment options
• Overall Response Rate (ORR) of 6% (2/36) and Disease Control Rate (DCR) of 36% (13/36) in the intent to treat population; both partial responses are confirmed and durable
• Important additional data on safety and efficacy including 6 months Overall Survival (OS), Tumour Growth Kinetics, and details of the confirmed partial responses will be presented in the poster at ELCC

Immutep (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that new interim data from 2nd line NSCLC patients (Part B) of its phase II TACTI-002 trial has been published in an abstract today in advance of ESMO’s European Lung Cancer Congress (ELCC) 2022. ELCC 2022 will now be taking place in a virtual only format from 30 March 2022 to 2 April 2022. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.